Oxford Cannabinoid Technologies Holdings plc, the pharmaceutical company developing prescription cannabinoid medicines targeting the US$ multi-billion pain market is pleased to announce the formation of its Scientific Advisory Board (“SAB”).
With the Company’s current focus on the treatment of neuropathic pain conditions, the composition of the SAB will initially comprise Professor Robert Dworkin, Professor Anthony Dickenson, and Doctor Giorgio Lambru, together a team of innovators and clinicians with an emphasis on linking pre-clinical research, clinical trials and the care of patients.
The SAB will work closely with OCTP’s Chief Scientific Officer, Doctor Valentino Parravicini, to provide scientific guidance on the Company’s strategy and overall approach to clinical trials. Its initial focus will be to advise on the design of the Company’s upcoming phase 1 clinical trials for OCT130401 and OCT461201, anticipated in Q4 2022 and Q1 2023 respectively, to help OCTP best address the needs of patients. The SAB will also help to shape the Company’s approach as it looks beyond phase 1, to phase 2 clinical trials, in patients affected by debilitating pain conditions.
Read the full story here.
Date posted: 25 April 2022
Article tag: Oxford Cannabinoid Technologies
Share